Search
for

    Learn

    5 / 26 results

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

      learn Latanoprost

      glaucoma medication with hair follicle stimulant effects

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.